Discover.
Launch.
Build.
Transform.
● Recent Highlights
Syremis Therapeutics
Syremis is developing novel medicines to make a profound impact on the treatment of mental health.
Syremis Therapeutics
INLEXZO™
INLEXZO™ (gemcitabine intravesical system) an original asset from Taris Bio, (acquired by Johnson & Johnson in 2019) receives FDA approval. INLEXZO™ is a new, potentially practice-changing approach for treating patients with certain types of bladder cancer, addressing the need for additional options following unsuccessful BCG therapy and for patients refusing or ineligible for bladder removal surgery.
INLEXZO™ (gemcitabine intravesical system)
Azalea Therapeutics
Azalea is enabling precision genome engineering directly inside the body, with an initial focus on creating cancer immunotherapies in vivo.
Azalea Therapeutics
Element Science
Element Science receives FDA approval for the revolutionary Jewel® Patch Wearable Cardioverter Defibrillator. This milestone marks the beginning of a new era in protecting individuals at temporary risk of sudden cardiac arrest — with a device designed not just to save lives, but to do so without interrupting them.
Portfolio
Merida Biosciences
Merida is advancing a precision immunology approach for antibody-driven diseases that selectively and durably eliminate their pathogenic drivers. This approach, enabled by advances in protein engineering and immunology, has the potential to address numerous autoimmune and allergic conditions that are inadequately treated today.
Merida Biosciences